WEBSITE BSE:526445 NSE: INDRAYANI BI Inc. Year: 1992 Industry: Diversified My Bucket: Add Stock
Last updated: 11:12
Indrayani Biotech Ltd is a cutting-edge biotechnology company that specializes in the development and commercialization of innovative solutions for various sectors, including healthcare, agriculture, and environmental sustainability. With a strong focus on research and development, the company leverages advanced biotechnological techniques to create novel products and services. In the healthcare domain, Indrayani Biotech Ltd pioneers the development of groundbreaking pharmaceuticals, diagnostics, and therapeutic solutions, aiming to improve pa...Read More
Indrayani Biotech Ltd is a cutting-edge biotechnology company that specializes in the development and commercialization of innovative solutions for various sectors, including healthcare, agriculture, and environmental sustainability. With a strong focus on research and development, the company leverages advanced biotechnological techniques to create novel products and services. In the healthcare domain, Indrayani Biotech Ltd pioneers the development of groundbreaking pharmaceuticals, diagnostics, and therapeutic solutions, aiming to improve patient outcomes and address unmet medical needs. Their expertise extends to agricultural biotechnology, where they devise sustainable methods to enhance crop productivity, develop disease-resistant varieties, and promote efficient resource management. Indrayani Biotech Ltd also places significant emphasis on environmental sustainability by developing eco-friendly technologies, such as biofuels and waste management solutions. The company actively collaborates with academic institutions, research organizations, and industry partners to foster innovation and accelerate the translation of scientific advancements into practical applications. With a commitment to excellence and a passion for transformative biotechnology, Indrayani Biotech Ltd strives to make a positive impact on society and contribute to a healthier and more sustainable future. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹56 Cr.
Stock P/E -9.1
P/B 0.7
Current Price ₹12.2
Book Value ₹ 16.7
Face Value 10
52W High ₹20.4
Dividend Yield 0%
52W Low ₹ 6.1
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 40 | 39 | 44 | 32 | 31 | 17 | 51 | 29 | 36 | 35 |
| Other Income | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 2 | 2 | 1 |
| Total Income | 41 | 39 | 45 | 32 | 31 | 17 | 53 | 31 | 38 | 36 |
| Total Expenditure | 33 | 36 | 34 | 26 | 26 | 14 | 56 | 26 | 34 | 32 |
| Operating Profit | 7 | 4 | 11 | 6 | 5 | 3 | -3 | 5 | 4 | 4 |
| Interest | 1 | 1 | 6 | 1 | 1 | 1 | 7 | 1 | 2 | 2 |
| Depreciation | 1 | 1 | 1 | 4 | 3 | 1 | -2 | 3 | 1 | 1 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 6 | 1 | 5 | 1 | 1 | 0 | -8 | 0 | 1 | 0 |
| Provision for Tax | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | 6 | 1 | 5 | 1 | 1 | 0 | -9 | 0 | 1 | 0 |
| Adjustments | -2 | -0 | 0 | 0 | -1 | -0 | -0 | 0 | -1 | -0 |
| Profit After Adjustments | 3 | 1 | 5 | 1 | 1 | 0 | -9 | 0 | 0 | 0 |
| Adjusted Earnings Per Share | 0.9 | 0.2 | 1 | 0.2 | 0.1 | 0.1 | -1.9 | 0 | 0.1 | 0 |
| #(Fig in Cr.) | Mar 2011 | Mar 2012 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 39 | 58 | 50 | 21 | 62 | 163 | 166 | 130 | 151 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 4 | 1 | 3 | 8 |
| Total Income | 39 | 58 | 50 | 21 | 62 | 167 | 167 | 133 | 158 |
| Total Expenditure | 39 | 57 | 47 | 26 | 55 | 146 | 143 | 124 | 148 |
| Operating Profit | 1 | 1 | 3 | -5 | 7 | 22 | 25 | 10 | 10 |
| Interest | 0 | 0 | 1 | 2 | 2 | 6 | 10 | 12 | 12 |
| Depreciation | 0 | 0 | 1 | 0 | 1 | 3 | 4 | 3 | 3 |
| Exceptional Income / Expenses | 0 | 0 | 0 | -4 | 0 | -1 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 1 | -11 | 4 | 12 | 11 | -6 | -7 |
| Provision for Tax | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Profit After Tax | -0 | -0 | 1 | -11 | 4 | 12 | 10 | -6 | -8 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | -3 | -4 | 5 | -1 |
| Profit After Adjustments | -0 | -0 | 1 | -11 | 4 | 9 | 6 | -2 | -9 |
| Adjusted Earnings Per Share | -0.1 | -0.2 | 2.2 | -3.2 | 1.3 | 2.6 | 1.4 | -0.3 | -1.8 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -22% | 28% | 21% | 0% |
| Operating Profit CAGR | -60% | 13% | 27% | 0% |
| PAT CAGR | -160% | NAN% | NAN% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -39% | -46% | 14% | 6% |
| ROE Average | -9% | 15% | -9% | -1% |
| ROCE Average | 3% | 13% | 7% | 8% |
| #(Fig in Cr.) | Mar 2011 | Mar 2012 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 4 | 3 | 31 | 20 | 24 | 55 | 67 | 73 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | -7 | 9 | 27 |
| Borrowings | 2 | 0 | 7 | 8 | 7 | 29 | 67 | 65 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 1 | 6 | 4 | 0 |
| Total Current Liabilities | 4 | 9 | 14 | 12 | 19 | 72 | 87 | 102 |
| Total Liabilities | 10 | 12 | 51 | 40 | 51 | 156 | 234 | 268 |
| Fixed Assets | 6 | 6 | 17 | 15 | 17 | 57 | 62 | 58 |
| Other Non-Current Assets | 0 | 0 | 15 | 16 | 16 | 21 | 26 | 32 |
| Total Current Assets | 4 | 7 | 19 | 9 | 19 | 78 | 145 | 178 |
| Total Assets | 10 | 12 | 51 | 40 | 51 | 156 | 234 | 268 |
| #(Fig in Cr.) | Mar 2011 | Mar 2012 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 | 1 | 1 | 2 | 3 | 1 |
| Cash Flow from Operating Activities | 1 | 2 | 6 | 0 | 4 | 16 | -30 | -7 |
| Cash Flow from Investing Activities | -3 | -0 | -4 | -1 | -1 | -47 | -16 | 25 |
| Cash Flow from Financing Activities | 2 | -1 | -1 | -0 | -3 | 33 | 44 | -18 |
| Net Cash Inflow / Outflow | 0 | 1 | 1 | -1 | 1 | 2 | -2 | -0 |
| Closing Cash & Cash Equivalent | 0 | 1 | 1 | 1 | 2 | 3 | 1 | 0 |
| # | Mar 2011 | Mar 2012 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | -0.13 | -0.18 | 2.22 | -3.25 | 1.3 | 2.55 | 1.4 | -0.34 |
| CEPS(Rs) | 0.64 | 0.6 | 5 | -3.14 | 1.49 | 4.46 | 3.12 | -0.6 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 9.67 | 9.51 | 0.7 | 5.76 | 7.06 | 12.94 | 13.86 | 15.16 |
| Core EBITDA Margin(%) | 1.89 | 0.88 | 5.56 | -23.44 | 11.01 | 10.62 | 14.23 | 4.9 |
| EBIT Margin(%) | 1.18 | 0.73 | 3.93 | -43.83 | 10.28 | 11.02 | 12.68 | 4.71 |
| Pre Tax Margin(%) | 0.26 | 0.04 | 1.62 | -53.18 | 7.21 | 7.55 | 6.6 | -4.41 |
| PAT Margin (%) | -0.12 | -0.11 | 1.62 | -53.18 | 7.21 | 7.32 | 6.27 | -4.69 |
| Cash Profit Margin (%) | 0.59 | 0.38 | 3.65 | -51.01 | 8.28 | 9.38 | 8.56 | -2.1 |
| ROA(%) | -0.87 | -0.59 | 2.53 | -24.5 | 9.71 | 11.51 | 5.35 | -2.44 |
| ROE(%) | -2.84 | -1.85 | 43.42 | -112.29 | 20.23 | 34.86 | 19.41 | -9.25 |
| ROCE(%) | 16.17 | 7.69 | 7.85 | -23.16 | 16.38 | 22.45 | 14.4 | 3.19 |
| Receivable days | 13.19 | 22.13 | 41.11 | 102.23 | 55.92 | 49.36 | 76.31 | 137.64 |
| Inventory Days | 0 | 0 | 37.1 | 53.33 | 7.77 | 15.4 | 59.91 | 117.29 |
| Payable days | 0 | 0 | 60.37 | 111 | 40.71 | 50.99 | 112.97 | 134.44 |
| PER(x) | 0 | 0 | 3.77 | 0 | 23.51 | 22.14 | 35.18 | 0 |
| Price/Book(x) | 0 | 0 | 12 | 1.1 | 4.32 | 4.37 | 3.55 | 0.94 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.14 | 0.07 | 0.31 | 1.74 | 1.96 | 1.61 | 1.99 | 1.55 |
| EV/Core EBITDA(x) | 7.55 | 6.08 | 5.17 | -7.82 | 17.25 | 12.04 | 13.31 | 21.23 |
| Net Sales Growth(%) | 0 | 47.68 | -13.94 | -57.74 | 191.97 | 164.61 | 2.02 | -21.66 |
| EBIT Growth(%) | 277.55 | -8.17 | 362.02 | -571.81 | 168.48 | 183.55 | 17.39 | -70.89 |
| PAT Growth(%) | 84.14 | -39.87 | 1346.41 | -1489.05 | 139.59 | 168.74 | -12.64 | -158.6 |
| EPS Growth(%) | 74.47 | -39.97 | 1346.41 | -246.65 | 139.92 | 96.79 | -45.24 | -124.45 |
| Debt/Equity(x) | 0.62 | 0.53 | 54.18 | 0.79 | 0.74 | 1.17 | 1.71 | 1.99 |
| Current Ratio(x) | 1.01 | 0.77 | 1.4 | 0.78 | 0.97 | 1.08 | 1.67 | 1.74 |
| Quick Ratio(x) | 1.01 | 0.78 | 1.03 | 0.68 | 0.89 | 0.91 | 1.18 | 1.33 |
| Interest Cover(x) | 1.29 | 1.06 | 1.7 | -4.69 | 3.35 | 3.18 | 2.09 | 0.52 |
| Total Debt/Mcap(x) | 0 | 0 | 4.52 | 0.71 | 0.17 | 0.32 | 0.48 | 2.11 |
| # | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 44.84 | 33.63 | 33.57 | 33.48 | 33.4 | 33.28 | 33.28 | 33.28 | 33.26 | 33.26 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 13.11 | 7.58 | 6.75 | 4.07 | 2.53 | 2.19 | 0.55 | 0 | 0 | 0 |
| Public | 42.05 | 58.79 | 59.68 | 62.45 | 64.07 | 64.53 | 66.17 | 66.72 | 66.74 | 66.74 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.53 | 1.53 | 1.53 | 1.52 | 1.52 | 1.52 | 1.52 | 1.52 | 1.51 | 1.51 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0.45 | 0.35 | 0.31 | 0.19 | 0.12 | 0.1 | 0.03 | 0 | 0 | 0 |
| Public | 1.44 | 2.68 | 2.72 | 2.84 | 2.92 | 2.94 | 3.01 | 3.04 | 3.04 | 3.04 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3.42 | 4.55 | 4.55 | 4.55 | 4.55 | 4.55 | 4.55 | 4.55 | 4.55 | 4.55 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
